{"schema_version":"1","generated_at":"2026-11-04T21:44:02.991Z","data_as_of":"2026-11-04","url":"https://www.findmykol.com/kol/thomas-schmidt","json_url":"https://www.findmykol.com/kol/thomas-schmidt/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"thomas-schmidt","name":"Thomas Schmidt","credential":"MD","title":"Rheumatology physician, Iowa Arthritis and Osteoporosis Center","specialty":"Rheumatology","specialty_raw":"Rheumatology","therapeutic_area":"Rheumatology/Immunology","therapeutic_areas":["Rheumatology/Immunology"],"institution":"Iowa Arthritis and Osteoporosis Center","institution_url":"https://www.findmykol.com/institution/iowa-arthritis-and-osteoporosis-center","city":"Urbandale","state":"IA","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1245468768"},"summary":"Thomas Schmidt is Rheumatology physician, Iowa Arthritis and Osteoporosis Center at Iowa Arthritis and Osteoporosis Center. ClinicalTrials.gov lists 1 registered study with this person as an investigator.","overview":{"text":"Thomas Schmidt, MD, is Rheumatology physician, Iowa Arthritis and Osteoporosis Center. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 3 companies, 2 NIH-funded awards (1985–1986).","bullets":["Top research focus: Rheumatology/Immunology","1 registered trials on ClinicalTrials.gov","Open Payments reporting from 3 companies"],"generated_at":"2026-11-04"},"focus":{"indications":[{"label":"Pancreatic Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Rheumatology/Immunology"],"drugs_studied":{"total":3,"shown":3,"withheld":0,"rows":[{"name":"Cosentyx","generic":"Secukinumab","trials":0,"payments":2,"publications":0,"mentions":2},{"name":"Benlysta","generic":"Belimumab","trials":0,"payments":1,"publications":0,"mentions":1},{"name":"Ofev","generic":"Nintedanib","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":4,"shown":3,"withheld":1,"rows":[{"name":"Novartis Pharmaceuticals Corporation","trials":0,"payments":2,"mentions":2},{"name":"Boehringer Ingelheim Pharmaceuticals, Inc.","trials":0,"payments":1,"mentions":1},{"name":"GlaxoSmithKline, LLC.","trials":0,"payments":1,"mentions":1}]}},"scholarship":{"note":"Research metrics are not shown for this record: either no confident publication match for this name, or more than one clinician shares the matched author record."},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT01486329","title":"VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer","phase":"PHASE1","status":"COMPLETED","role":"Investigator","sponsor":"Vaximm GmbH","source_url":"https://clinicaltrials.gov/study/NCT01486329","trial_url":"https://www.findmykol.com/trial/NCT01486329"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":2025},"rows_total":4,"shown":3,"withheld":1,"rows":[{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":91.77,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245468768"},{"payer":"GlaxoSmithKline, LLC.","program_year":2023,"amount_usd":19.37,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245468768"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2022,"amount_usd":84.55,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245468768"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1245468768","source":"payments"},"prescribing":{"data_year":2024,"areas_total":9,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":71.2,"classes_total":8,"classes":[{"class":"Interleukin-6 Receptor Antagonist","setting":"mixed","share_pct":44.8,"drugs":[{"name":"Tocilizumab","share_pct":100},{"name":"Actemra","share_pct":0}],"max_beneficiaries":null},{"class":"TNF inhibitor","setting":"mixed","share_pct":20.1,"drugs":[{"name":"Certolizumab pegol","share_pct":49.3},{"name":"Golimumab","share_pct":36.5},{"name":"Infliximab","share_pct":13.4},{"name":"Humira(Cf) Pen","share_pct":0.5},{"name":"Humira(Cf)","share_pct":0.1},{"name":"Enbrel Sureclick","share_pct":0.1},{"name":"Enbrel","share_pct":0.1}],"max_beneficiaries":null}]},{"area":"Musculoskeletal","share_pct":27,"classes_total":7,"classes":[{"class":"Other drugs affecting bone structure and mineralization","setting":"administered","share_pct":19.4,"drugs":[{"name":"Romosozumab-aqqg","share_pct":100}],"max_beneficiaries":28},{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":7,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":81}]},{"area":"Metabolism & gastrointestinal","share_pct":0.5,"classes_total":3,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":0.4,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":159},{"class":"Aminosalicylate","setting":"prescribed","share_pct":0.1,"drugs":[{"name":"Sulfasalazine","share_pct":53.4},{"name":"Sulfasalazine Dr","share_pct":46.6}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":1985,"last":1986},"rows_total":44,"shown":3,"withheld":41,"rows":[{"project":"R01EY036676","title":"Wellbeing and Health Among Low Vision and Blind Youth","fiscal_year":2026,"amount_usd":717379,"organization":"TEXAS TECH UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R01EY036676"},{"project":"R01AI170137","title":"Using Disadvantage Indices in Pandemic Vaccine Allocation and Beyond to Promote Health Opportunity","fiscal_year":2026,"amount_usd":667593,"organization":"UNIVERSITY OF PENNSYLVANIA","source_url":"https://reporter.nih.gov/quickSearch/R01AI170137"},{"project":"R01AI170137","title":"Using Disadvantage Indices in Pandemic Vaccine Allocation and Beyond to Promote Health Opportunity","fiscal_year":2025,"amount_usd":767180,"organization":"UNIVERSITY OF PENNSYLVANIA","source_url":"https://reporter.nih.gov/quickSearch/R01AI170137"}],"source":"grants"},"publications":{"total":0,"shown":0,"withheld":0,"recent":[],"source":"works"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD","source_url":"https://doctors.unitypoint.org/provider/thomas-schmidt/1164123","status":"verified","collected_at":"2026-11-04"}]},"roles":{"total":1,"shown":1,"rows":[{"value":"Fellow, American College of Rheumatology","source_url":"https://events.arthritis.org/pages/3537","status":"provisional","collected_at":"2026-11-04"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"2020 Walk to Cure Arthritis Medical Honoree (Team IAOC)","source_url":"https://events.arthritis.org/pages/3537","status":"provisional","collected_at":"2026-11-04"}]}},"similar":[{"name":"David Felson","slug":"david-felson","institution":"Boston University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/david-felson","json_url":"https://www.findmykol.com/kol/david-felson/profile.json"},{"name":"Marc Hochberg","slug":"marc-hochberg","institution":"University of Maryland School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/marc-hochberg","json_url":"https://www.findmykol.com/kol/marc-hochberg/profile.json"},{"name":"Philip Mease","slug":"philip-mease","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/philip-mease","json_url":"https://www.findmykol.com/kol/philip-mease/profile.json"},{"name":"Michelle Petri","slug":"michelle-petri","institution":"Johns Hopkins University School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/michelle-petri","json_url":"https://www.findmykol.com/kol/michelle-petri/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":1,"funding":41}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-04"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-11-04"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-11-04"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}